MMC blog header

The department joins an elite group of practices across the country that have been recognized for their commitment to continuous quality improvement and a patient-centered approach to care.

Murfreesboro Medical Clinic’s (MMC) OBGYN department, which provides the full spectrum in obstetrical and gynecological care to women in Middle Tennessee, has been recognized by the National Committee for Quality Assurance (NCQA) as a Patient-Centered Specialty Practice (PCSP). 

Following an intensive vetting process based on industry-leading best practices, the department was notified that it had achieved this status which recognizes its commitment to continuous quality improvement and a patient-centered approach to care. With this announcement, MMC OBGYN becomes not only the first obstetrical and gynecological practice, but the first specialty practice in the state of Tennessee to earn this prestigious recognition.

“This is a huge accomplishment and one that we are all very proud of,” said Denise Flanagan, MMC’s Chief Operating Officer. “It demonstrates our physicians’ and staff’s commitment to excellence and the patients that we serve.”

What is a Patient-Centered Specialty Practice?

Practices that become recognized under Patient-Centered Specialty Practice Recognition have demonstrated commitment to patient-centered care and clinical quality through: streamlined referral processes and care coordination with referring clinicians, timely patient and caregiver-focused care management and continuous clinical quality.

“NCQA Patient-Centered Specialty Practice Recognition distinguishes practices that communicate, collaborate and integrate care in ways that patients want and that improve quality,” said NCQA President Margaret E. O’Kane. “I commend the team at Murfreesboro Medical Clinic Obstetrics and Gynecology for its achievement, and for its commitment to continuous improvement.”

Earning NCQA Patient-Centered Specialty Practice Recognition shows consumers, private payers and government agencies that the practice has undergone a rigorous review of its capabilities and is committed to sharing information and coordinating care. Recognition also signals to primary care practices that the specialty practice is ready to be an effective partner in caring for patients. 

“The OBGYN department has done an excellent job transforming their practice into a Patient Centered Specialty Practice,” said Collette Thomas, MMC’s Quality Coordinator. “The strain of the pandemic has not made this an easy process. Revising existing workflows and implementing new processes that ensure coordinated care took a great deal of teamwork and collaboration. I’m thrilled to see it all come together.”

“I am very proud of this accomplishment,” added Jason Pollock, M.D. of MMC OBGYN. “In a year as trying as this one, these victories should be celebrated. It is not often you are apart of a group that is the ‘first and only.’ I’d like to thank our Office Manager Christy Kinslow and our Quality Coordinator Collette Thomas for their leadership navigating this accreditation process.”

MMC’s OBGYN department joins a distinguished group of fewer than 400 other specialty care practices from across the United States that have also earned PCSP Recognition.


Learn More:

To learn more about the NCQA’s Patient-Centered Specialty Practice Recognition program, please visit the committee’s website.

To learn more about MMC’s OBGYN physicians and services, visit the department’s website.

From its inception in 1949, the physicians and staff of Murfreesboro Medical Clinic have created a true healthcare community in Rutherford County, providing all patients with a holistic,multidisciplinary approach to everyday wellness. Drs. Carl Adams and S.C.Garrison founded Murfreesboro Medical Clinic with the lofty goal of providing convenient, quality care to all Rutherford County residents. Though the clinic has experienced a variety of changes and expansions throughout its 70 years of care, the physicians and staff of MMC have continued to pursue Adam’sand Garrison’s core values of care, compassion and community in every endeavor.

Now in 2019, MMC remains a multispecialty, physician-owned medical group with over 80 physicians and 20 different departments who are still committed to offering patients both primary and specialty care within their community. Today, MMC has over 700 employees and five locations across Murfreesboro.

“As our community continues to grow, it is imperative that its medical community grows as well to ensure that we have access to quality healthcare provided by excellent physicians instate-of-the-art medical facilities,” shares Joey Peay, Chief Executive Officer.“At Murfreesboro Medical Clinic, we remain committed to meeting those goals. It is my belief that Drs. Adams and Garrison would beam with a strong smile and a well-deserved sense of pride if they could see what MMC has become and how it continues to provide quality medical care to this community,” Peay continues.

MMC is proud to celebrate its 70 years of caring for its patients and community.

Posted by Murfreesboro Medical Clinic | Topic: News  | Category: Recognition & Awards


Leadership at Murfreesboro Medical Clinic and SurgiCenter realized several years ago that genomics and precision medicine were the future of healthcare and would be invaluable in helping provide better, safer therapies

By Nicholas Cote, D.O.

Article via Healthcare Innovation


As healthcare leaders look toward the future, most envision a clinical environment where providers are equipped and empowered to deliver personalized and precise care to their patients. Advances in genomic science over the past decade have provided insights that will enable organizations to transform the way they diagnose and treat both common and rare conditions.

Yet this progress has been slow to arrive at the point of care. Hospitals, health systems and medical groups are striving to develop strategies that allow their clinicians to leverage this critical information to improve quality of care and patient satisfaction.

Interestingly, ambulatory groups are among the leaders in adopting precision medicine, overtaking many larger organizations and academic centers, especially in pharmacogenomics (PGx). Because it delivers information about how well patients will metabolize specific medications based on their genetic profile, PGx has practical (and highly valuable) application across virtually all specialties. Impacting prescribing decisions in real time, PGx results help clinicians identify the most effective medication first, rather than relying on the traditional trial-and-error approach. In addition, these tests can flag if a drug might cause side effects (which impact how closely a patient follows the care plan) and even if it could prove unsafe or toxic.

Leadership at Murfreesboro Medical Clinic and SurgiCenter (MMC) realized several years ago that genomics and precision medicine were the future of healthcare and would be invaluable in helping provide better, safer therapies. Providers began to order PGx tests when they felt the information would benefit their treatment decisions (and thereby their patients). Initial efforts centered on psychiatric and behavioral health medications (e.g., antidepressants and anti-anxiety drugs) and common cardiovascular treatments (e.g., statins, clopidogrel). Both providers and patients saw immediate value and were excited about the potential for expanded usage.

Three barriers impeded MMC’s ability to scale its precision program, however:

1.      The cost of testing. Payer policies around reimbursement are lagging and patients often are required the cover the cost. This proved to be an obstacle. While most patients intuitively recognized how valuable PGx information could be, they understandably balked at the added expense. Although prices have dropped dramatically in the past year or two, it was not so long ago that they ran into the thousands – well out of reach for the average patient.

2.       Lack of understanding about how PGx factors into clinical decision making. Again, while the concept of PGx testing is easy to grasp, operational questions remained. Although most medical schools now include coursework on genomics, providers practicing today have varying degree of familiarity with this area of science. And they have a lot of questions such as: When should I order a PGx test? Does every patient need to have one? What happens if a patient’s PGx test indicates that she should change medications – but the alternative is not fully covered by insurance?

3.       Lack of convenient – and understandable – access to PGx test results. To date, PGx test results are returned as a paper document or a scanned attachment in the medical record. Since results could not be saved as discreet data or integrated with other patient information, providers had to A) realize/remember the data was available somewhere in the record; B) leave their workflow and find it; and C) figure out what the test results meant in context of their patient’s condition.

It was important to MMC’s leadership and care teams to achieve success with precision medicine, and so MMC proactively addressed each of these barriers.

First, we reached out to a lab partner that specializes in PGx testing and asked if we could negotiate a pricing model to help our patients. The partner was accommodating and agreed on a cap for patients qualifying for financial assistance. Previously, we learned patients seemed to have a $100 threshold for out-of-pocket expenses and were able to stay within that price point.

Next, we began to investigate technology partners that could help MMC bring the PGx results directly into the clinical workflow. Ultimately, we adopted a solution that ingests genomic data from the lab (and can handle additional labs as we expand) and integrates it with clinical information so providers see the complete picture within the patient context. Providers can access the PGx information with one click from their EHR, and from there can dive deeper into test results or link out to evidence-based materials if they want more information.

And, of course, we are training providers and addressing operational issues on an ongoing basis. As the organization becomes more familiar with PGx, we are working out the processes, procedures, workflows and decision support to guide day-by-day precision medicine practices.

Bringing the power of pharmacogenomics to the point of care has produced a multitude of benefits.

·         Patients are receiving better care. MMC has had patients diagnosed with depression, for instance, who have spent months working with their physician trying to come up with the best medication at the most appropriate dose. With ready access to genomic insights, providers can prescribe a more effective therapy much earlier in the treatment cycle. Less time is lost and the quality of the patient’s life is better. One patient messaged his physician through the portal saying MMC had “changed his life” through the simple PGx test.

·         Providers feel empowered. I like to say that having genomic data available makes us feel more “doctor-y.” Clinicians have been frustrated by having to practice trial-and-error medicine for so long. PGx test results, available within the patient context and connected to current knowledgebases, mean providers have a more complete picture. They can bring all their training and skills to bear when making clinical decisions.

·         MMC has differentiated itself within its service area. Patients in our region have many choices for healthcare: Nashville is just minutes away and other urban centers, like Atlanta, are within easy driving distance. Because there are many healthcare providers nearby, MMC is dedicated to leveraging all the talent and technology available to ensure our patients receive superior care. I like to say that, with precision medicine, we are on the bleeding edge, not just the cutting edge. We have had one patient tell us that the reason they chose us as their provider was our PGx program.

It is not often that an innovation of this magnitude comes along. Placing critical genomic information directly into the hands of providers, right at the point of clinical decision making, represents one such breakthrough. MMC and its patients will continue to explore the value PGx can deliver – and look beyond to additional utilization of genomic insights in areas like disease risk identification (e.g., cardiovascular) and targeted therapies for select conditions (e.g., cancer).

A primary care provider, Nicolas Cote, D.O., also serves as Chief Medical Information Officer and President of the Murfreesboro Medical Clinic and SurgiCenter in Tennessee.

Murfreesboro Medical Clinic | 615-893-4480 | see all locations
pixel image